Biosceptre's Phase 1 Clinical Trial for anti-cancer vaccine BIL06v approved by Ethics Committee
The proposed Phase I clinical trial for BIL06v (anti-cancer vaccine) was granted conditional approval by the Bellberry Ethics committee on 21st February 2018.
By: Biosceptre International
CAMBRIDGE, England - March 1, 2018 - PRLog -- On the 21st of February Biosceptre's proposed Phase I clinical trial for BIL06v (anti-cancer vaccine) was granted conditional approval by the Bellberry Ethics committee. Biosceptre is now proceeding to take BIL06v into a Phase I trial in late Q2 or early Q3 2018.
Biosceptre has high confidence in the safety of BIL06v, in part as a result of pre-clinical studies and compassionate access patients treated in Australia under the TGA's Special Access Scheme.
The planned clinical trial will recruit between 20 and 30 patients from a basket of late stage cancers and seeks to confirm safety, tolerability and immunogenicity of BIL06v. The planned clinical trial will also seek to identify early indications of efficacy in humans.
CEO Gavin Currie said, "Having recently closed entry to our Series A fund raising round, we are pleased that this fully funded clinical trial, building on significant preclinical data, has been conditionally approved. We consider that a successful clinical trial, our first for a systemic therapeutic product targeting nfP2X7, will provide further validation of nfP2X7. We are hopeful for first patient recruitment in Q2 2018."
Biosceptre is a Cambridge UK headquartered biotechnology company focused on developing next generation cancer treatments targeting nfP2X7. Biosceptre's clinical product pipeline includes vaccines and systemic antibody-based therapeutics to treat a range of cancer types, as well as a topical product for skin cancers.
nfP2X7 is critical to the avoidance of cell death by cancer cells. The target allows cells to avoid programmed cell death signals in the tumour environment, and may provide growth and metastatic advantages. Biosceptre's focus is on validation and exploitation of this novel immuno-oncology target by multiple therapeutic modalities including vaccine, antibody, and cell therapy (Car-T).
This unique cancer target is present on almost all of the top 20 cancers, as well as most of the rarest cancers, with a global average presence on tumours across these cancers of approximately50%
Biosceptre believes the discovery of nfP2X7 will be a fundamental development for cancer therapy.